Clinical trials: Mania
Mania, Bipolar I
Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old
This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders.
- Conditions
- Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder
- Trial name
- NCT01932541
- Testing
- Latuda (Lurasidone)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, New Occurred Episode
Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR
The primary purpose of the study is to explore management of symptomatology in patients with bipolar disorder that experience a new manic,depressive or mixed episode and are treated with Seroquel XR monotherapy/adjuctive, in…
- Trial name
- NCT01029145
- Where
- 30 sites in Romania
- Volunteers
- 537 people
- Sponsor
- AstraZeneca
Major Depression, Bipolar Disorder
Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
The goal of this project is to study the course and outcome of illness in individuals who present with a first episode of depression or mania, or who have a recurrent disorder but have never received treatment.
- Trial name
- NCT01529905
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- McMaster University
Impulsivity, Bipolar Disorder
CBT for Problematic Impulsive Behaviours in Bipolar Disorder: A Case Series / CBT-PIB
The goal of this case series is to explore whether a talking therapy, specifically Cognitive Behavioural Therapy (CBT) is acceptable and feasible in the management of mood-driven impulsive behaviours in people with bipolar…
- Conditions
- Impulsivity, Bipolar Disorder, Hypomania, Bipolar I Disorder
- Trial name
- NCT06129500
- Testing
- Cognitive Behavioural Therapy for Problematic Impulsive Behaviours
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Exeter
Bipolar I Disorder
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/day over 52 weeks in patients who completed the 3-week double-blind study CLIC477D2301.
- Trial name
- NCT00228059
- Testing
- Licarbazepine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Major Depressive Disorder
Lithium Versus Paroxetine in Major Depression
This study is being done to look at how well people respond to two different drug treatments for depression. Clinically, people can respond differently to different treatments for reasons which are not always clear.
- Trial name
- NCT01416220
- Testing
- Lithium, Paroxetine
- Where
- Canada
- Sponsor
- Nova Scotia Health Authority
Bipolar Disorder, Mania
Peroxisomal Defects and Familial Risk for Bipolar Disorder
The purpose of this study is to screen for peroxisome defects in child and adolescent offspring of Bipolar Disorder I (BD-I) parents at different stages of risk for transitioning to mania and following the onset of mania.
- Trial name
- NCT01237379
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
Bipolar Disorder With Manic or Mixed Episodes
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder.
- Trial name
- NCT00374920
- Testing
- MEM 1003
- Where
- 21 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memory Pharmaceuticals
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Bipolar Disorder
Risk Factors for AD-Associated Switch to Mania
The present study aimed at identifying clinical risk factors for switch into (hypo)mania or mixed states, within 8 weeks after introduction of an antidepressant or after increasing its dosage.
- Trial name
- NCT01503489
- Testing
- Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.
- Where
- Spain
- Volunteers
- 221 people
- Sponsor
- Hospital Clinic of Barcelona
Bipolar Disorder
Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
This 26-week open-label extension study is designed to provide information on the safety and tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term administration in children and adolescents…
- Trial name
- NCT03768726
- Testing
- Ziprasidone
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Schizoaffective Disorder
Probiotics to Prevent Relapse After Hospitalization for Mania
The purpose of this study is to determine if taking a probiotic supplement versus a placebo will lower rates of relapse and improve the clinical course among participants who have been hospitalized for mania.
- Trial name
- NCT01731171
- Testing
- Probiotic Supplement, Inert Compound
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sheppard Pratt Health System
Bipolar I Disorder
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.
- Trial name
- NCT00238485
- Testing
- Licarbazepine
- Volunteers
- 251 people
- Sponsor
- Novartis
Bipolar Disorder
Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who…
- Trial name
- NCT00191997
- Testing
- Olanzapine
- Where
- 11 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Manic
Magnetic Seizure Therapy for Bipolar Mania
This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety for bipolar mania. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy…
- Trial name
- NCT03160664
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System, treatment as usual (TAU)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Mental Health Center
Bipolar Disorder
Functional and Neurochemical Brain Changes in First-episode Bipolar Mania
The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with bipolar disorder who are being treated with either quetiapine or lithium.
- Trial name
- NCT00609193
- Testing
- lithium, quetiapine
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Cincinnati
Bipolar Disorder
The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
The purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania
- Trial name
- NCT00216554
- Testing
- risperidone
- Volunteers
- 118 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar Disorder
Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded…
- Trial name
- NCT00109577
- Testing
- MCN36 (nutritional supplement)
- Where
- 2 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Bipolar Disorder, Mania
Safety and Efficacy Study of Lithium in Bipolar Disorder
The purpose of this study is to determine whether Lithium is safe and effective in the treatment of Bipolar I Disorder subjects with symptoms of acute mania.
- Trial name
- NCT00422331
- Testing
- Lithium Carbonate Capsule
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- JDS Pharmaceuticals